Brief: Newron cannot predict how long coronavirus will delay schizophrenia trial
31/03/2020 16:54
March 31 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* ANTICIPATES A DELAY IN START OF ITS PLANNED STUDIES WITH
EVENAMIDE IN SCHIZOPHRENIA DUE TO HOSPITAL STAFF BEING SHIFTED
TO CORONAVIRUS CASES, AWAY FROM RESEARCH
* CANNOT PREDICT HOW LONG COVID-19 PANDEMIC WILL DELAY
INITIATION
OF ITS CLINICAL TRIALS
Source text for Eikon: ID:
Further company coverage: NWRN.S
(Reporting by John Miller)
((J.Miller@thomsonreuters.com;))
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study